A systematic review of persistence and compliance with bisphosphonates for osteoporosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-02-17

AUTHORS

J. A. Cramer, D. T. Gold, S. L. Silverman, E. M. Lewiecki

ABSTRACT

Fourteen reports utilizing data from de-identified administrative databases were reviewed. Studies contained at least one measure of patient persistence or compliance with bisphosphonates or bisphosphonates and other anti-osteoporosis medications. These studies confirm that women with osteoporosis have suboptimal persistence and compliance rates with bisphosphonate therapy.IntroductionThis review summarizes patient persistence and compliance with bisphosphonates for the treatment of osteoporosis.MethodsWe conducted a MEDLINE search for the period from January 1998 to May 2006, using a detailed list of terms related to persistence and compliance with anti-osteoporosis medications. Studies were included if they contained at least one measure of persistence or compliance derived from de-identified administrative databases containing patient demographics and prescription information.ResultsWe reviewed 14 reports, which described 14 databases. The percentage of patients persisting with therapy for 1 year ranged from 17.9% to 78.0%. Compliance, assessed as mean medication possession ratio (MPR), ranged from 0.59 to 0.81. When comparing compliance with weekly and daily bisphosphonates, the mean MPR was consistently higher for weekly versus daily therapy (0.58 to 0.76 versus 0.46 to 0.64 for patients receiving weekly and daily bisphosphonate therapy respectively). Persistence was also improved in patients receiving weekly bisphosphonates, assessed by both length of persistence (194 to 269 days [weekly] and 134 to 208 days [daily]) and percentage of persistent patients at the end of the follow-up period (35.7% to 69.7% [weekly] and 26.1% to 55.7% [daily]).ConclusionAlthough patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal. More... »

PAGES

1023-1031

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8

DOI

http://dx.doi.org/10.1007/s00198-006-0322-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012288373

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17308956


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hormone Replacement Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Compliance", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cramer", 
        "givenName": "J. A.", 
        "id": "sg:person.01132106034.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132106034.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Medical Center, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gold", 
        "givenName": "D. T.", 
        "id": "sg:person.0657120700.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657120700.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Silverman", 
        "givenName": "S. L.", 
        "id": "sg:person.0750301114.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750301114.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA", 
          "id": "http://www.grid.ac/institutes/grid.419992.e", 
          "name": [
            "New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lewiecki", 
        "givenName": "E. M.", 
        "id": "sg:person.0756034765.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756034765.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-003-1431-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032558418", 
          "https://doi.org/10.1007/s00198-003-1431-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-004-1652-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023624379", 
          "https://doi.org/10.1007/s00198-004-1652-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002230020037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038583086", 
          "https://doi.org/10.1007/s002230020037"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0073-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020337646", 
          "https://doi.org/10.1007/s00198-006-0073-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-005-1957-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035467750", 
          "https://doi.org/10.1007/s00198-005-1957-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0085-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019542455", 
          "https://doi.org/10.1007/s00198-006-0085-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1502-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013179474", 
          "https://doi.org/10.1007/s00198-003-1502-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-02-17", 
    "datePublishedReg": "2007-02-17", 
    "description": "Fourteen reports utilizing data from de-identified administrative databases were reviewed. Studies contained at least one measure of patient persistence or compliance with bisphosphonates or bisphosphonates and other anti-osteoporosis medications. These studies confirm that women with osteoporosis have suboptimal persistence and compliance rates with bisphosphonate therapy.IntroductionThis review summarizes patient persistence and compliance with bisphosphonates for the treatment of osteoporosis.MethodsWe conducted a MEDLINE search for the period from January 1998 to May 2006, using a detailed list of terms related to persistence and compliance with anti-osteoporosis medications. Studies were included if they contained at least one measure of persistence or compliance derived from de-identified administrative databases containing patient demographics and prescription information.ResultsWe reviewed 14 reports, which described 14 databases. The percentage of patients persisting with therapy for 1\u00a0year ranged from 17.9% to 78.0%. Compliance, assessed as mean medication possession ratio (MPR), ranged from 0.59 to 0.81. When comparing compliance with weekly and daily bisphosphonates, the mean MPR was consistently higher for weekly versus daily therapy (0.58 to 0.76 versus 0.46 to 0.64 for patients receiving weekly and daily bisphosphonate therapy respectively). Persistence was also improved in patients receiving weekly bisphosphonates, assessed by both length of persistence (194 to 269\u00a0days [weekly] and 134 to 208\u00a0days [daily]) and percentage of persistent patients at the end of the follow-up period (35.7% to 69.7% [weekly] and 26.1% to 55.7% [daily]).ConclusionAlthough patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-006-0322-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "mean medication possession ratio", 
      "anti-osteoporosis medications", 
      "daily therapy", 
      "patient persistence", 
      "administrative databases", 
      "percentage of patients", 
      "medication possession ratio", 
      "treatment of osteoporosis", 
      "suboptimal persistence", 
      "daily bisphosphonates", 
      "bisphosphonate medication", 
      "bisphosphonate therapy", 
      "persistent patients", 
      "patient demographics", 
      "weekly bisphosphonates", 
      "possession ratio", 
      "MEDLINE search", 
      "bisphosphonates", 
      "systematic review", 
      "compliance rate", 
      "length of persistence", 
      "overall compliance", 
      "prescription information", 
      "patients", 
      "therapy", 
      "medications", 
      "osteoporosis", 
      "persistence rates", 
      "compliance", 
      "regimens", 
      "review", 
      "MethodsWe", 
      "percentage", 
      "persistence", 
      "study", 
      "women", 
      "demographics", 
      "period", 
      "database", 
      "ResultsWe", 
      "treatment", 
      "measures", 
      "rate", 
      "report", 
      "years", 
      "search", 
      "data", 
      "list", 
      "end", 
      "measures of persistence", 
      "ratio", 
      "length", 
      "detailed list", 
      "information", 
      "terms", 
      "mean MPR", 
      "ConclusionAlthough patients", 
      "weekly bisphosphonate medication"
    ], 
    "name": "A systematic review of persistence and compliance with bisphosphonates for osteoporosis", 
    "pagination": "1023-1031", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012288373"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-006-0322-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17308956"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-006-0322-8", 
      "https://app.dimensions.ai/details/publication/pub.1012288373"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_445.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-006-0322-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-006-0322-8'


 

This table displays all metadata directly associated to this object as RDF triples.

222 TRIPLES      22 PREDICATES      102 URIs      87 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-006-0322-8 schema:about N2848a6097dbb4cf1a4b7d89bfce999c3
2 N4e001ce56ce04ecbaf371c602e644d18
3 N513a3f51d41c40b7ac1a9f16440fc24b
4 N6e4e3a9d4a474daaae5404c82d65a1a4
5 N85738164e29a43a29c5abda5a6d7e081
6 N8717d2049b404fdb973799c47a8612c1
7 N93aa1bb1556142069c9c8dc3a8e856dc
8 Nab778f4e0d8a40c5879072a12d26a7fa
9 Nc24a98268f2345f88f588437b34a87b0
10 Ndabd6ffa1786496388d1032fdf6e3db8
11 Nfabca0aa8dd9403e9a895f68ef48e4dc
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author N870245c43068408c98de2205b0e0ab2b
15 schema:citation sg:pub.10.1007/s00198-003-1431-2
16 sg:pub.10.1007/s00198-003-1502-4
17 sg:pub.10.1007/s00198-004-1652-z
18 sg:pub.10.1007/s00198-005-1957-6
19 sg:pub.10.1007/s00198-006-0073-6
20 sg:pub.10.1007/s00198-006-0085-2
21 sg:pub.10.1007/s002230020037
22 schema:datePublished 2007-02-17
23 schema:datePublishedReg 2007-02-17
24 schema:description Fourteen reports utilizing data from de-identified administrative databases were reviewed. Studies contained at least one measure of patient persistence or compliance with bisphosphonates or bisphosphonates and other anti-osteoporosis medications. These studies confirm that women with osteoporosis have suboptimal persistence and compliance rates with bisphosphonate therapy.IntroductionThis review summarizes patient persistence and compliance with bisphosphonates for the treatment of osteoporosis.MethodsWe conducted a MEDLINE search for the period from January 1998 to May 2006, using a detailed list of terms related to persistence and compliance with anti-osteoporosis medications. Studies were included if they contained at least one measure of persistence or compliance derived from de-identified administrative databases containing patient demographics and prescription information.ResultsWe reviewed 14 reports, which described 14 databases. The percentage of patients persisting with therapy for 1 year ranged from 17.9% to 78.0%. Compliance, assessed as mean medication possession ratio (MPR), ranged from 0.59 to 0.81. When comparing compliance with weekly and daily bisphosphonates, the mean MPR was consistently higher for weekly versus daily therapy (0.58 to 0.76 versus 0.46 to 0.64 for patients receiving weekly and daily bisphosphonate therapy respectively). Persistence was also improved in patients receiving weekly bisphosphonates, assessed by both length of persistence (194 to 269 days [weekly] and 134 to 208 days [daily]) and percentage of persistent patients at the end of the follow-up period (35.7% to 69.7% [weekly] and 26.1% to 55.7% [daily]).ConclusionAlthough patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf N6230155f7d8344a18a2d6de58a1f2025
29 Nf1dd67e39eab4dee88dd6d081aef55c1
30 sg:journal.1100834
31 schema:keywords ConclusionAlthough patients
32 MEDLINE search
33 MethodsWe
34 ResultsWe
35 administrative databases
36 anti-osteoporosis medications
37 bisphosphonate medication
38 bisphosphonate therapy
39 bisphosphonates
40 compliance
41 compliance rate
42 daily bisphosphonates
43 daily therapy
44 data
45 database
46 demographics
47 detailed list
48 end
49 information
50 length
51 length of persistence
52 list
53 mean MPR
54 mean medication possession ratio
55 measures
56 measures of persistence
57 medication possession ratio
58 medications
59 osteoporosis
60 overall compliance
61 patient demographics
62 patient persistence
63 patients
64 percentage
65 percentage of patients
66 period
67 persistence
68 persistence rates
69 persistent patients
70 possession ratio
71 prescription information
72 rate
73 ratio
74 regimens
75 report
76 review
77 search
78 study
79 suboptimal persistence
80 systematic review
81 terms
82 therapy
83 treatment
84 treatment of osteoporosis
85 weekly bisphosphonate medication
86 weekly bisphosphonates
87 women
88 years
89 schema:name A systematic review of persistence and compliance with bisphosphonates for osteoporosis
90 schema:pagination 1023-1031
91 schema:productId N23f8af3fbb564ed697c52533e1935fc7
92 N6959625e0c0741faa9f2f58115ab1d9f
93 Ne42aa2d7aad8438ea37bb8b85f4011dc
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012288373
95 https://doi.org/10.1007/s00198-006-0322-8
96 schema:sdDatePublished 2021-12-01T19:19
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N342f3d6459dd4aa097855ed3d900f8e9
99 schema:url https://doi.org/10.1007/s00198-006-0322-8
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N23f8af3fbb564ed697c52533e1935fc7 schema:name pubmed_id
104 schema:value 17308956
105 rdf:type schema:PropertyValue
106 N2848a6097dbb4cf1a4b7d89bfce999c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Drug Administration Schedule
108 rdf:type schema:DefinedTerm
109 N342f3d6459dd4aa097855ed3d900f8e9 schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 N4e001ce56ce04ecbaf371c602e644d18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Hormone Replacement Therapy
113 rdf:type schema:DefinedTerm
114 N513a3f51d41c40b7ac1a9f16440fc24b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Bone Density Conservation Agents
116 rdf:type schema:DefinedTerm
117 N6230155f7d8344a18a2d6de58a1f2025 schema:issueNumber 8
118 rdf:type schema:PublicationIssue
119 N65eab628a5c44eee94d3e6b9f88cd89f rdf:first sg:person.0657120700.21
120 rdf:rest Nfbb54cdd703048e6acb59609b55f8b78
121 N6959625e0c0741faa9f2f58115ab1d9f schema:name doi
122 schema:value 10.1007/s00198-006-0322-8
123 rdf:type schema:PropertyValue
124 N6e4e3a9d4a474daaae5404c82d65a1a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Patient Compliance
126 rdf:type schema:DefinedTerm
127 N85738164e29a43a29c5abda5a6d7e081 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Osteoporosis
129 rdf:type schema:DefinedTerm
130 N870245c43068408c98de2205b0e0ab2b rdf:first sg:person.01132106034.52
131 rdf:rest N65eab628a5c44eee94d3e6b9f88cd89f
132 N8717d2049b404fdb973799c47a8612c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Middle Aged
134 rdf:type schema:DefinedTerm
135 N93aa1bb1556142069c9c8dc3a8e856dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Adult
137 rdf:type schema:DefinedTerm
138 Nab778f4e0d8a40c5879072a12d26a7fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Osteoporosis, Postmenopausal
140 rdf:type schema:DefinedTerm
141 Nc24a98268f2345f88f588437b34a87b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Nda8eccab0ecf4e8c9f6b7844094e8a39 rdf:first sg:person.0756034765.55
145 rdf:rest rdf:nil
146 Ndabd6ffa1786496388d1032fdf6e3db8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Female
148 rdf:type schema:DefinedTerm
149 Ne42aa2d7aad8438ea37bb8b85f4011dc schema:name dimensions_id
150 schema:value pub.1012288373
151 rdf:type schema:PropertyValue
152 Nf1dd67e39eab4dee88dd6d081aef55c1 schema:volumeNumber 18
153 rdf:type schema:PublicationVolume
154 Nfabca0aa8dd9403e9a895f68ef48e4dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Diphosphonates
156 rdf:type schema:DefinedTerm
157 Nfbb54cdd703048e6acb59609b55f8b78 rdf:first sg:person.0750301114.52
158 rdf:rest Nda8eccab0ecf4e8c9f6b7844094e8a39
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
163 schema:name Clinical Sciences
164 rdf:type schema:DefinedTerm
165 sg:journal.1100834 schema:issn 0937-941X
166 1433-2965
167 schema:name Osteoporosis International
168 schema:publisher Springer Nature
169 rdf:type schema:Periodical
170 sg:person.01132106034.52 schema:affiliation grid-institutes:grid.47100.32
171 schema:familyName Cramer
172 schema:givenName J. A.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132106034.52
174 rdf:type schema:Person
175 sg:person.0657120700.21 schema:affiliation grid-institutes:grid.189509.c
176 schema:familyName Gold
177 schema:givenName D. T.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657120700.21
179 rdf:type schema:Person
180 sg:person.0750301114.52 schema:affiliation grid-institutes:grid.19006.3e
181 schema:familyName Silverman
182 schema:givenName S. L.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750301114.52
184 rdf:type schema:Person
185 sg:person.0756034765.55 schema:affiliation grid-institutes:grid.419992.e
186 schema:familyName Lewiecki
187 schema:givenName E. M.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756034765.55
189 rdf:type schema:Person
190 sg:pub.10.1007/s00198-003-1431-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032558418
191 https://doi.org/10.1007/s00198-003-1431-2
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/s00198-003-1502-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013179474
194 https://doi.org/10.1007/s00198-003-1502-4
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/s00198-004-1652-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023624379
197 https://doi.org/10.1007/s00198-004-1652-z
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s00198-005-1957-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035467750
200 https://doi.org/10.1007/s00198-005-1957-6
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s00198-006-0073-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337646
203 https://doi.org/10.1007/s00198-006-0073-6
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s00198-006-0085-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019542455
206 https://doi.org/10.1007/s00198-006-0085-2
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s002230020037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038583086
209 https://doi.org/10.1007/s002230020037
210 rdf:type schema:CreativeWork
211 grid-institutes:grid.189509.c schema:alternateName Duke University Medical Center, Durham, NC, USA
212 schema:name Duke University Medical Center, Durham, NC, USA
213 rdf:type schema:Organization
214 grid-institutes:grid.19006.3e schema:alternateName Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA
215 schema:name Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA
216 rdf:type schema:Organization
217 grid-institutes:grid.419992.e schema:alternateName New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
218 schema:name New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
219 rdf:type schema:Organization
220 grid-institutes:grid.47100.32 schema:alternateName Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA
221 schema:name Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, 06516-2770, West Haven, CT, USA
222 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...